Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Breast Neoplasms 9Ovarian Neoplasms 2Neoplasm Metastasis 2Lymphatic Abnormalities 2Lymphangioma, Cystic 2Lymphangioma 2Vascular Malformations 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Diseases, Vascular 1Recurrence 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Hyperglycemia 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1HER2-positive Metastatic Breast Cancer 1Genetic Diseases, Inborn 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Arteriovenous Malformations 1Advanced HER2+Breast Cancer 1Advanced Breast Cancer 1

Interventions

pembrolizumab 57Nivolumab 50Ipilimumab 31Specimen Handling 23Magnetic Resonance Spectroscopy 19Cyclophosphamide 14Biopsy 11fludarabine 10binimetinib 10Opdualag 10trametinib 9relatlimab 9Radiosurgery 9CTLA-4 Antigen 9dabrafenib 8lifileucel 7fludarabine phosphate 7aldesleukin 7encorafenib 6Interleukin-2 6cemiplimab 5atezolizumab 5Paclitaxel 5Blood Specimen Collection 5X-Rays 4Taxes 4Pemetrexed 4Gemcitabine 4Cisplatin 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Alpelisib × 90 days × Clear all
NCT06545682 2026-04-16

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

M.D. Anderson Cancer Center

Phase 1 Recruiting
50 enrolled
BreastDermatologic

Breast Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡